PMID- 34015320
OWN - NLM
STAT- MEDLINE
DCOM- 20211105
LR  - 20211105
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 904
DP  - 2021 Aug 5
TI  - TRP channels in cancer pain.
PG  - 174185
LID - S0014-2999(21)00338-1 [pii]
LID - 10.1016/j.ejphar.2021.174185 [doi]
AB  - Chronic pain is a common symptom experienced during cancer progression. 
      Additionally, some patients experience bone pain caused by cancer metastasis, 
      which further complicates the prognosis. Cancer pain is often treated using 
      opioid-based pharmacotherapy, but these drugs possess several adverse effects. 
      Accordingly, new mechanisms for cancer pain management are being explored, 
      including transient receptor potential channels (TRPs). TRP ion channels are 
      expressed in several tissues and play a key role in pain detection, especially 
      TRP vanilloid 1 (TRPV1) and TRP ankyrin 1 (TRPA1). In the present review, we 
      describe the role of TRPV1 and TRPA1 involved in cancer pain mechanisms. Several 
      studies have revealed that the administration of TRPV1 or TRPA1 
      agonists/antagonists and TRPV1 or TRPA1 knockdown reduced sensitivity to 
      nociception in cancer pain models. TRPV1 was also found to be involved in various 
      models of cancer-induced bone pain (CIBP), with TRPV1 expression reportedly 
      enhanced in some models. These studies have demonstrated the TRPV1 or TRPA1 
      association with cancer pain in models induced by tumour cell inoculation into 
      the bone cavity, hind paw, mammary fat pad, and sciatic nerve in mice or rats. To 
      date, only resiniferatoxin, a TRPV1 agonist, has been evaluated in clinical 
      trials for cancer pain and showed preliminary positive results. Thus, TRP 
      channels are potential targets for managing cancer-related pain syndromes.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - de Almeida, Amanda Spring
AU  - de Almeida AS
AD  - Programa de Pos-Graduacao Em Farmacologia, Universidade Federal de Santa Maria 
      (UFSM), 97105-900, Santa Maria, RS, Brazil.
FAU - Bernardes, Laura de Barros
AU  - Bernardes LB
AD  - Programa de Pos-Graduacao Em Farmacologia, Universidade Federal de Santa Maria 
      (UFSM), 97105-900, Santa Maria, RS, Brazil.
FAU - Trevisan, Gabriela
AU  - Trevisan G
AD  - Programa de Pos-Graduacao Em Farmacologia, Universidade Federal de Santa Maria 
      (UFSM), 97105-900, Santa Maria, RS, Brazil. Electronic address: 
      gabrielatrevisansantos@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210517
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (TRPA1 Cation Channel)
RN  - 0 (TRPV Cation Channels)
RN  - 0 (Transient Receptor Potential Channels)
SB  - IM
MH  - Animals
MH  - Cancer Pain/*drug therapy/*physiopathology
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Pain Management
MH  - TRPA1 Cation Channel/agonists/antagonists & inhibitors/metabolism
MH  - TRPV Cation Channels/agonists/antagonists & inhibitors/metabolism
MH  - Transient Receptor Potential Channels/agonists/antagonists & 
      inhibitors/genetics/*metabolism
OTO - NOTNLM
OT  - Cancer-induced bone pain
OT  - Capsaicin
OT  - Opioids
OT  - Resiniferatoxin
OT  - TRPA1
OT  - TRPV1
EDAT- 2021/05/21 06:00
MHDA- 2021/11/06 06:00
CRDT- 2021/05/20 20:12
PHST- 2020/11/18 00:00 [received]
PHST- 2021/05/06 00:00 [revised]
PHST- 2021/05/12 00:00 [accepted]
PHST- 2021/05/21 06:00 [pubmed]
PHST- 2021/11/06 06:00 [medline]
PHST- 2021/05/20 20:12 [entrez]
AID - S0014-2999(21)00338-1 [pii]
AID - 10.1016/j.ejphar.2021.174185 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2021 Aug 5;904:174185. doi: 10.1016/j.ejphar.2021.174185. Epub 
      2021 May 17.